Regulus Therapeutics Inc (NASDAQ:RGLS) has been assigned a consensus recommendation of “Hold” from the nine research firms that are presently covering the firm, MarketBeat Ratings reports. Nine investment analysts have rated the stock with a hold rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $1.13.
Several equities research analysts have recently issued reports on RGLS shares. Wedbush reissued a “hold” rating and issued a $1.00 price objective on shares of Regulus Therapeutics in a research report on Friday, August 10th. Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a research report on Friday, August 10th. Finally, Zacks Investment Research lowered shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th.
Shares of Regulus Therapeutics stock traded down $0.04 during trading hours on Monday, hitting $1.61. The company’s stock had a trading volume of 90,266 shares, compared to its average volume of 355,925. Regulus Therapeutics has a 1-year low of $1.04 and a 1-year high of $17.28. The firm has a market capitalization of $14.44 million, a P/E ratio of -0.14 and a beta of 1.78.
A hedge fund recently raised its stake in Regulus Therapeutics stock. Renaissance Technologies LLC increased its position in Regulus Therapeutics Inc (NASDAQ:RGLS) by 396.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 595,501 shares of the biopharmaceutical company’s stock after purchasing an additional 475,512 shares during the quarter. Renaissance Technologies LLC owned 6.82% of Regulus Therapeutics worth $118,000 as of its most recent filing with the Securities and Exchange Commission.
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.
Featured Story: What is an SEC Filing?
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.